Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2004-10-22
2008-12-02
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C426S063000
Reexamination Certificate
active
07459286
ABSTRACT:
Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine treatment of the patient immediately at presentation in the emergency room.
REFERENCES:
patent: 5122534 (1992-06-01), Loose et al.
patent: 5731208 (1998-03-01), Heinecke
patent: 5747274 (1998-05-01), Jackowski
patent: 5871946 (1999-02-01), Lucas et al.
patent: 5889042 (1999-03-01), MacLean et al.
patent: 5985272 (1999-11-01), Deby et al.
patent: 6096556 (2000-08-01), Heinecke
patent: 6133039 (2000-10-01), Heinecke
patent: 6268220 (2001-07-01), Heinecke
patent: 6953666 (2005-10-01), Kinkade, Jr. et al.
patent: 7223552 (2007-05-01), Hazen et al.
patent: 2002/0164662 (2002-11-01), Hazen et al.
patent: 2003/0119792 (2003-06-01), Roca
patent: 2003/0180218 (2003-09-01), Hazen
patent: 2006/0051872 (2006-03-01), Sailor et al.
patent: 0 389 381 (1990-09-01), None
patent: 0 418 486 (1991-03-01), None
patent: 96/04311 (1996-02-01), None
patent: 02/48715 (2002-06-01), None
patent: 02/50550 (2002-06-01), None
patent: WO 02/062207 (2002-08-01), None
Baldus S et al (published online Sep. 2, 2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, vol. 108, pp. 1440-1445.
Biasucci LM et al (1996) Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Amer Coll Cardiol, vol. 27, No. 3, pp. 611-616.
Zhang R et al (Mar. 1, 2002) Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusable substrates for myeloperoxidase in plasma. Blood, vol. 99, No. 5, pp. 1802-1810.
“Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease” by Zhang, et al.,JAMA, vol. 286, No. 17, Nov. 7, 2001, pp. 2136-2142.
“Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?” by Steinberg, et al.,Circulation, 2002; 105:2107-2111.
“Myeloperoxidase Deficiency” by Nauseef,Hematology, Oncology Clinics of North America, vol. 2, No. 1, Mar. 1988, pp. 135-158.
“Primary Inherited Defects in Neutrophil Function: Etiology and Treatment” by Malech, et al.,Seminars in Hematology, vol. 34, No. 4, Oct. 1997, pp. 279-290.
“Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall” by Heinecke, et al.,FASEB J., 13, 1113-1120 (1999).
“Myeloperoxidase-Generated Oxidants and Atherosclerosis” by Podrez, et al.,Free Radical Biology&Medicine, vol. 28, No. 12, pp. 1717-1725, Jan. 2000.
“Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions” by Daugherty, et al.,J. Clin. Invest., vol. 94, Jul. 1994, 437-444.
“3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low-Density Lipoprotein Isolated from Human Atherosclerosis Intima” by Hazen, et al.,J. Clin. Invest., vol. 99, No. 9, May 1997, 2075-2081.
Elevated levels of protein-boundp-hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in hun fatty streaks, intermediate lesions and advanced atherosclerosis lesions by Hazen, et al.,Biochem J. (2000) 352, 693-699.
“p-Hydroxypheylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima” by Heller, et al.,The Journal of Biological Chemistry, vol. 275, No. 14, Apr. 7, 2000, pp. 9957-9962.
International Search Report dated Jul. 31, 2002.
“Oxidized LDL and HDL: antagonists in atherothrombosis” by Mertens, et al.,FASEB J., 15, 2073-2084 (2001).
“Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species” by Podrez, et al.,J. Clin. Invest. 105:1095-1108 (2000).
“Inhibition of Adhesion Molecules Markedly Ameliorates Cytokine-Induced Sustained Myocardial Dysfunction in Dogs in vivo” by Momii, et al.,J. Mol. Cell. Cardiol. 30, 2637-2650 (1998).
“Supplemention with Tetrahydrobiopterin Suppresses the Development of Hypertension in Spontaneously Hypertension Rats” by Hong, et al.,Hypertension, 2001; 38:1044-1048.
Supplementary European Search Report dated Jan. 29, 2004.
“Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II” by Marquez, et al.,The Journal of Biological Chemistry, vol. 270, No. 51, Dec. 22, 1995, pp. 30434-30440.
“Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum” by Schmitt, et al.,Biochemistry, 1999, 38, 16904-16915.
“Nitric Oxide Modulates the Catalytic Activity of Myeloperoxidase” by Abu-Soud, et al.,The Journal of Biological Chemistry, vol. 275, No. 8, Feb. 25, 2000, pp. 5425-5430.
“Circulating Myeloperoxidase and Anti-Myeloperoxidase Antibody in Patients with Vasculitis” by Minota, et al.,Scand J. Rheumatol, 1999;25:94-9.
“Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels” by Downs, et al.,JAMA, May 27, 1998, vol. 279, No. 20, pp. 1615-1622.
“The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels” by Sacks, et al.,The New England Journal of Medicine, vol. 335, No. 14, Oct. 3, 1996, pp. 1001-1009.
“Byeond Cholesterol: Modifications of Low-Density Lipoprotein that Increase its Atherogenecity” by Steinberg, et al.,The New England Journal of Medicine, vol. 320, No. 14, Apr. 16, 1989, pp. 915-924.
“Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors” by Takemoto, et al.,Arterioscler Throm Vasc Biol, 2001;21:1712-1719.
“The Evolving Role of Statins in the Management of Atherosclerosis” by Vaughan, et al.,Journal of the American College of Cardiology, vol. 35, No. 1, 2000, pp. 1-10.
“Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients with Hypercholesterolemia” by Locatelli, et al.,Arch Neurol, vol. 59, Feb. 2002, pp. 213-216.
“Alzehimer's Disease: Bad for the Heart, Bad for the Mind” by Marx,Science, vol. 294, Oct. 19, 2001, pp. 508-509.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase in mRNA in Alzheimer and control brain by Yasojima, et al.,Clinical Neuroscience and Neuropathology, vol. 12, No. 13, Sep. 17, 2001, pp. 2935-2938.
“Lovastatin Treatment Decreases Mononuclear Cell Infiltration Into the CNS of Lewis Rats with Experimental Allergic Encephalomyelitis” by Stanislaus, et al.,Journal of
Hazen Stanley L.
Penn Marc S.
Zhang Renliang
Calfee Halter & Griswold LLP
Martin Paul C.
The Cleveland Clinic Foundation
Weber Jon P
LandOfFree
Assessing the risk of a major adverse cardiac event in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessing the risk of a major adverse cardiac event in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessing the risk of a major adverse cardiac event in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4052167